Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1752 | Honey Wiki | 1.00 |
| drug2520 | Nebulized Platelet Lysate Wiki | 1.00 |
| drug2546 | Nigella Sativa / Black Cumin Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.
Description: Changes in pre and post treatment spirometry measures
Measure: Spirometry-FVC and FEV1/FVC tests Time: 4 weeks; 8 weeksDescription: Changes from pre and post treatment spirometry measures
Measure: Spirometry-FVC and FEV1/FVC tests Time: 3 months, 6 monthsDescription: Changes in distance walked during 6MWD test from pre to post treatment
Measure: 6 Minute Walk Distance test (6MWD) Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Changes in distance-desaturation product from 6MWD from pre to post treatment
Measure: Distance-desaturation product from 6MWD Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Changes in San Diego Shortness of Breath Questionnaire (SOBQ) score from pre to post; treatment; scores range from 0-120 with higher scores equaling greater breathing impairment
Measure: San Diego Shortness of Breath Questionnaire (SOBQ) Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Changes in SF-36 scores from pre to post treatment; 8 subscales 0-100 range where lower scores equal more disability
Measure: Short Form-36 (SF-36) Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Average SANE score post treatment; scores range from 0-100 where 0=no improvement and 100=100% improvement in breathing condition
Measure: Modified Single Assessment Numeric Evaluation (SANE) Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: changes in medications from pre to post treatment
Measure: Medications Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Incidence of adverse events after treatment
Measure: Incidence of adverse events Time: 4 weeks; 8 weeks; 3 months; 6 monthsDescription: Incidence of surgical/other treatment interventions after treatment
Measure: Incidence of surgical/other treatment interventions Time: 4 weeks; 8 weeks; 3 months; 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports